The 2nd edition of Asebio Investor Day attracted around 300 participants and 60 international investors Blog Post

26 September saw the 2nd edition of the Asebio Investor Day, which was organised by Asebio with the collaboration of Barcelona Science Park (PCB), the Biotechnology Markets Platform) ICEX Spain Trade and Investment and the Alternative Spanish Equity Market. Droplite, Molomics, Ona Therapeutics and SOM Biotech, all based at PCB, were among 50 companies selected to present their projects at the financing forum, in which 57 investors from 10 countries around the world participated.

 

Oncoheroes Biosciences and Boehringer Ingelheim sign exclusive licensing agreement for Volasertib Blog Post

Oncoheroes Biosciences –a Boston-based biotech company with its European headquarters at the Barcelona Science Park– and Boehringer Ingelheim International GmbH (Boehringer Ingelheim) have signed a worldwide exclusive licensing contract for Volasertib. Under the terms of this agreement the global pharmaceutical group assigns the intellectual property of this anti-cancer compound to Oncoheroes, which is committed to further its development and commercialization for pediatric cancer indications.

 

EIT Health Spain awards Headstart Programme support to Senolytic Therapeutics and Moirai Biodesign Blog Post

EIT Health Spain has announced today the 15 Spanish start-ups selected for 2019 Headstart Programe, which includes funding, mentoring and networking opportunities. Among those selected are Senolytic Therapeutics and Moirai Biodesign based in the Barcelona Science Park. Since 2016 the Spanish node of EIT Health, located in the Park, has supported more than 100 Spanish start-ups through a variety of acceleration programmes designed to support healthcare entrepreneurs at every stage of their business journey.

 

A Eugin study wins the Clinical Science Award for best clinical poster at ESHRE 2019 Blog Post

The fresh or frozen eggs of the same woman are equally fertile. This is the main conclusion of a study conducted by Eugin Group researchers which won the Clinical Science Award for best clinical poster at the 35th Annual Meeting of the European Society of Human Reproduction and Embryology (ESHRE). The research went head-to-head with 800 other studies, and its principal investigator was David Cornet-Bartolomé, a member of Eugin’s Basic Research Laboratory headquartered in the Barcelona Science Park.

 

M. Miralpeix Pharma Consulting establishes its headquarters at the Barcelona Science Park Blog Post

M. Miralpeix Pharma Consulting, specialized in providing scientific and strategic advice to companies and public and private research centres linked to life sciences and healthcare, has opened its headquarters at the Barcelona Science Park. The objective of the consultancy firm is to interact in an ecosystem that enables it to strengthen its links with the main players in the pharmaceutical and biotech sector to boost its R&D&I projects towards a more advanced phase, closer to the market.

 

Biocat Report shows growth in international investment in BioRegion of Catalonia Blog Post

More than 300 professionals from the sector attended the event to present a new edition of the Biocat Report, the benchmark study on the healthcare and life sciences sector in Catalonia. Under de title “Escaling-up the BioRegion of Catalonia”, the Biocat Report highlights the growing attractiveness of the life sciences and health sector for international investment –linked to the positioning of the BioRegion as a European hub in health research–, the increase in the number of companies and the occupation of sector, as well as the advance of innovation in health towards social impact. Biocat, the organization that coordinates and promotes the life sciences sector in Catalonia, has its headquarters in the Barcelona Science Park.

 

AELIX Therapeutics and Gilead Sciences enter into a clinical research collaboration agreement for HIV Cure Blog Post

AELIX Therapeutics, a clinical-stage biotechnology company based in the Barcelona Science Park and specialized in the discovery and development of immunotherapies for HIV infection, announces that it has entered into a clinical research collaboration with Gilead Sciences, a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. Both companies will jointly evaluatejointly evaluate proprietary investigational products in a strategic clinical study aimed at achieving a functional cure of HIV infection.